Assignment 3(Week3)_ - TEVA PHARMACEUTICALS INDUSTRIES LTD 1 TEVA PHARMACEUTICALS INDUSTRIES LTD Teva Pharmaceuticals Industries Ltd TEVA

Assignment 3(Week3)_ - TEVA PHARMACEUTICALS INDUSTRIES LTD...

This preview shows page 1 - 4 out of 7 pages.

TEVA PHARMACEUTICALS INDUSTRIES, LTD 1 TEVA PHARMACEUTICALS INDUSTRIES, LTD Teva Pharmaceuticals Industries, Ltd.
Image of page 1
TEVA PHARMACEUTICALS INDUSTRIES, LTD 2 Abstract Pharmaceutical companies are undertaking major transformations to be able to manage the innovative challenges of the contemporary economy. Some of the influences compelling these transformations are adopting the business, the variety and intricacy of new drugs, and the fading security offered by patents ( Papageorgiou & Shah, 2001 ). Operating in 60 countries with 46,000 employees worldwide, Teva is the largest generic drug manufacturer in the world. It clings to a communal set of values and vision aside from being dynamic and diverse. This paper talks about how Teva competes in the generic pharmaceutical industry and its competitive advantage. Evaluating the company’s resources identifying the most valuable ones. In addition to that, opportunities for Teva in innovative and generic pharmaceuticals will be discussed. Furthermore, things the firm should consider moving forward for their continued success will also be mentioned. Keywords: Pharmaceutical, innovative, generic, competitive advantage
Image of page 2
TEVA PHARMACEUTICALS INDUSTRIES, LTD 3 Teva Pharmaceuticals Industries, Ltd Pharmaceutical companies are undertaking major transformations to be able to manage the innovative challenges of the contemporary economy. Some of the influences compelling these transformations are adopting the business, the variety and intricacy of new drugs, and the fading security offered by patents. The emergent of new drugs to the organization of the industry and allocation systems affects every phases of the corporate value chain (Papageorgiou & Shah, 2001). Pharmaceutical firms are being required by market demands to interpret their product portfolio in a more comprehensive view. The normal life cycles of latest medications are becoming terser. Development of new product might take 8 years and the investment on it must be recouped swiftly as generic counterparts can be developed at a later time that will decrease its worth. Thus, businesses are continuously challenged with the question of the best consumption of
Image of page 3
Image of page 4

You've reached the end of your free preview.

Want to read all 7 pages?

  • Winter '14
  • Barrett
  • Business, Generic drug, Teva, Teva Pharmaceutical Industries, TEVA PHARMACEUTICALS INDUSTRIES

  • Left Quote Icon

    Student Picture

  • Left Quote Icon

    Student Picture

  • Left Quote Icon

    Student Picture